Sec. 14. 32 MRSA §13794, as enacted by PL 1987, c. 710, §5, is amended to read:

§13794. Labeling of prescriptions

Every drug dispensed pursuant to prescription, whether for a legend drug or not, shall must carry on the label the following information: The the prescription number; the date of filling; the patient's name; directions for use; the name and strength of the drug and the amount dispensed, including either the brand name of the drug or, if a generic and therapeutically equivalent drug is dispensed, it shall must be in accordance with section 13781; the beyond use date of the drug; the name of the practitioner prescribing the drug; and the name, address and telephone number of the pharmacy where the prescription was compounded and dispensed. For purposes of this section, "beyond use date" means a date beyond which the contents of the prescription are not recommended to be used.

Sec. 15. Statutory Review Committee

1. Establishment. The Commissioner of Professional and Financial Regulation shall establish a statutory review committee within 30 days of the effective date of this Act. The size and composition of the committee is determined by the commissioner, except that, membership must include a licensed pharmacist in independent practice, a representative of a corporate pharmacy chain, a licensed pharmacist working in an institutional setting, a consumer representative and a representative of prescribing practitioners. At least one pharmacist member must be a member of the Board of Pharmacy.

2. Charge. The committee is charged with the following duties:

A. To review the current scope of practice for pharmacists, as set forth in the Maine Revised Statutes, Title 32, section 13702, subsection 22 and to recommend whether changes should be made to reflect current professional practices or prospective professional practices that would be advantageous to the public. The discussion regarding scope of practice must include, but is not limited to, drug or device administration and collaborative practice.

B. To review the adequacy of the current regulatory relationship between the Maine Board of Pharmacy and institutional pharmacies and propose changes if necessary.